Copyright ©The Author(s) 2017.
World J Gastroenterol. Nov 14, 2017; 23(42): 7495-7504
Published online Nov 14, 2017. doi: 10.3748/wjg.v23.i42.7495
Table 1 Current medications that have been used for treatment of non- alcoholic fatty liver disease
MedicationMechanismEffect on histologyRecommended by AASLD/EASL
PioglitazonePPAR-γImprovement of steatosis, lobular inflammation and ballooningYes
Vitamin EAnti-oxidantImprovement of hepatocyte ballooningYes
MetforminAmelioration of IRNo beneficial effectNo
StatinsHMG-CO A reductase inhibitionNo beneficial effectsNo
EzetimibeInhibition of cholesterol absorptionImprovement of hepatocyte ballooningNo
FibratesPPAR-αImprovement of hepatocyte ballooningNo
PentoxifyllineInhibition of TNF-α and anti-oxidantsImprovement of inflammation and ballooningNo
LosartanARBImprovement of steatosis, lobular inflammation, ballooning and fibrosisNo
UDCAPrevention of apoptosis/inflammationLacking dataNo
Synbiotic and probioticsModulation of gut microbiotaLacking dataNo
Table 2 Emerging medications for treatment of non- alcoholic fatty liver disease
MedicationMechanismHistology benefit
Obeticholic acidFarnesoid X receptor agonistImprovement of steatosis, lobular inflammation, ballooning and fibrosis
AramcholInhibition of SCD1Lacking data
ElafibranorPPAR α/δ agonistImprovement of steatosis and fibrosis
CenicrivirocInhibition of CCR2/CCR5Lacking data
LiraglutideGlucagon-like peptide-1 agonistImprovements in steatosis and hepatocyte ballooning